PACB (Pacific Biosciences of California) PS Ratio: 3.08 (As of Jun. 30, 2026) — 58% Below Median


PACB Pacific Biosciences of California Inc PACB
54 GF Score
Price $1.64
GF Value $1.62
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Pacific Biosciences of California PS Ratio?

Pacific Biosciences of California PACB -5.76% 54 PS Ratio is 3.08 as of Jun. 30, 2026, which is 58% below its 10-year median of 7.29. GuruFocus rates PACB with a GF Score™ of 54/100 and a GF Value™ of $1.62 (Fairly Valued). The stock has 7 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Pacific Biosciences of California ranks worse than 53.98% on this metric.

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Pacific Biosciences of California's share price is $1.635. Pacific Biosciences of California's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.53. Hence, Pacific Biosciences of California's PS Ratio for today is 3.08.

The historical rank and industry rank for Pacific Biosciences of California's PS Ratio or its related term are showing as below:

PACB' s PS Ratio Range Over the Past 10 Years
Min: 1.78   Med: 7.29   Max: 113.08
Current: 3.07

During the past 13 years, Pacific Biosciences of California's highest PS Ratio was 113.08. The lowest was 1.78. And the median was 7.29.

PACB's PS Ratio is ranked worse than
53.98% of 804 companies
in the Medical Devices & Instruments industry
Industry Median: 2.94 vs PACB: 3.07

Pacific Biosciences of California's Revenue per Sharefor the three months ended in Mar. 2026 was $0.12. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.53.

Warning Sign:

Pacific Biosciences of California Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Pacific Biosciences of California was 2.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -2.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 1.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was -6.20% per year.

During the past 13 years, Pacific Biosciences of California's highest 3-Year average Revenue per Share Growth Rate was 38.90% per year. The lowest was -22.00% per year. And the median was 2.05% per year.

Back to Basics: PS Ratio


Pacific Biosciences of California  (NAS:PACB) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Pacific Biosciences of California PS Ratio Related Terms


Pacific Biosciences of California PS Ratio Historical Data

* Premium members only.

The historical data trend for Pacific Biosciences of California's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacific Biosciences of California PS Ratio Chart

Pacific Biosciences of California Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.02 14.33 12.40 3.43 3.51

Pacific Biosciences of California Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.27 2.39 2.55 3.51 2.49

PACB vs KIDS, MOBI, SI: PS Ratio Comparison

For the Medical Devices subindustry, Pacific Biosciences of California's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacific Biosciences of California PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's PS Ratio distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's PS Ratio falls into.


PACB
54GF Score
Pacific Biosciences of California Inc PACB
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacific Biosciences of California PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Pacific Biosciences of California's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.635/0.53
=3.08

Pacific Biosciences of California's Share Price of today is $1.635.
Pacific Biosciences of California's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.53.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Frequently Asked Questions Learn more about PS Ratio →
What does a PS Ratio of 3.08 mean?
Pacific Biosciences of California (PACB) has a PS Ratio of 3.08 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pacific Biosciences of California and its competitors. This is 58% below median its historical median of 7.29. Over the past decade, Pacific Biosciences of California's PS Ratio has ranged from 1.78 to 113.08. According to the industry distribution chart, Pacific Biosciences of California ranks #434 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 54%.
Is Pacific Biosciences of California's PS Ratio too high?
Pacific Biosciences of California's current PS Ratio of 3.08 is 58% below median its 10-year median of 7.29. Over the past 10 years, this metric has ranged from a low of 1.78 to a high of 113.08. The Medical Devices & Instruments industry median PS Ratio is 2.94. Pacific Biosciences of California's value of 3.08 is 4.8% above this industry median. Based on the distribution chart, Pacific Biosciences of California ranks #434 out of 804 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Pacific Biosciences of California has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's PS Ratio compare to KIDS and MOBI?
According to the Medical Devices & Instruments industry distribution chart, Pacific Biosciences of California ranks #434 out of 804 companies for PS Ratio. This places Pacific Biosciences of California in the lower half of its industry. The industry median PS Ratio is 2.94. Pacific Biosciences of California's value of 3.08 is 4.8% above this benchmark. Historically, Pacific Biosciences of California's own PS Ratio has ranged from 1.78 to 113.08 over the past decade. While the company's 10-year median is 7.29 vs. the industry median of 2.94, Pacific Biosciences of California has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Biosciences of California's current PS Ratio of 3.08 is 4.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pacific Biosciences of California and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Biosciences of California's current PS Ratio is 3.08, which is 58% below median its own 10-year median of 7.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.62, compared to a current price of $1.64 — trading 0.9% above its estimated fair value. The current PS Ratio is 3.08, which is 58% below median its 10-year median of 7.29 and 4.8% above the Medical Devices & Instruments industry median of 2.94. Pacific Biosciences of California's overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current PS Ratio is 3.08 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Biosciences of California (PACB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be overvalued. The current stock price of $1.64 is trading 0.9% above its estimated GF Value™ of $1.62. GuruFocus considers Pacific Biosciences of California to be Fairly Valued.

Key valuation signals for PACB:

  • PS Ratio: 3.08 (58% below median its 10-year median of 7.29)
  • GF Value™: $1.62 vs. price of $1.64 (0.9% above fair value)
  • GF Score™: 54/100 with 7 warning signs
  • Industry Position: 4.8% above the Medical Devices & Instruments median (#434 of 804)

No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacific Biosciences of California Business Description

Other Exchanges P09:Germany
Address 1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
54GF Score

Get the complete analysis for PACB

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.64
Price
$1.62
GF Value